Phase I study of pomalidomide in relapsed or refractory Waldenstrom macroglobulinemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Pomalidomide (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 17 Jun 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 13 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 18 Aug 2015 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History